Although there was no difference in CXCL13 serum concentrations between the healthy control group and patients without evidence of disease (Figure 5), we found significantly elevated serum concentrations of CXCL13 in patients with metastatic disease as compared with normal controls and with breast cancer patients without evidence of disease after surgical removal of their original tumour. Here, CXCL13 is linked to metastatic neoplasm.